Malignant melanoma is the most common oral tumor in dogs. Overrepresented breeds include miniature poodle, dachshund, Scottish terrier, cocker spaniel, chow chow, and golden retriever. Most dogs that develop oral malignant melanoma (OMM) are older; there is no gender predilection. OMM must be differentiated from other malignant tumors of the oral cavity (e.g., squamous cell carcinoma, fibrosarcoma) as well as benign oral tumors and inflammatory and hyperplastic lesions, which are more prevalent than oral malignancies.

**PRESENTATION AND CLINICAL SIGNS**
Affected dogs may be asymptomatic. In these cases, an oral mass is often discovered by the owner or during a routine physical examination or dental prophylactic procedure. Clinical signs of OMM include halitosis, excessive drooling, bleeding from the oral cavity, dysphagia, facial swelling, and pain on mouth manipulation. OMMs are often pigmented (FIGURE 1), but up to 38% can be amelanotic. The most common locations are the gingiva, lips, tongue, and hard palate.

**DIAGNOSIS**
In some cases, especially if a tumor is pigmented, the diagnosis of OMM may be confirmed with cytology of a fine-needle aspirate. An incisional
punch or a wedge biopsy, often in conjunction with immunohistochemistry (IHC), is needed for most nonpigmented oral tumors, as amelanotic melanoma can histologically mimic a poorly differentiated sarcoma or epithelial tumor. Application of IHC antibodies such as Melan-A, S-100, PNL2, TRP-1, and TRP-2 may be recommended by a pathologist to help reach a definitive diagnosis.11-13

Excisional biopsies result in incomplete margins and should be avoided when possible. If a tumor is small and an excisional biopsy is unavoidable, accurate documentation of tumor size and location, including photographs, is important for planning further treatment. Biopsy should always be performed from within the oral cavity. Special care should be taken to avoid contaminating normal tissue.

**STAGING**

Staging for OMM (TABLE 1) should include blood work (complete blood count and serum biochemistry profile), urinalysis, assessment of regional lymph nodes, and imaging of the thoracic cavity. Submandibular lymph nodes are the only palpable regional lymph nodes. Both ipsilateral and contralateral nodes should be aspirated regardless of size. Up to 40% of normal-sized lymph nodes may contain metastatic disease.15

Three-view thoracic radiography or thoracic computed tomography (CT) should be used to screen for pulmonary metastasis. Abdominal ultrasonography, although not routinely performed, should be considered to rule out metastasis to the liver and other intra-abdominal organs as well as comorbidities unrelated to melanoma.

Preoperative cross-sectional imaging of the head and neck is imperative for surgical planning, especially for tumors arising from the hard palate, caudal maxilla, or caudal mandible (FIGURE 2). Both CT and magnetic resonance imaging (MRI) are more sensitive than radiography for assessing the extent of invasion into the surrounding tissues, including bone. CT scans provide better bone detail than MRI. Cross-sectional imaging also allows assessment of the nonpalpable parotid and medial retropharyngeal lymph nodes.

**TREATMENT**

**Surgery**

Surgery is the best means of achieving locoregional tumor control.16 When OMMs are excised, margins of at least 2 cm of normal tissue should be taken in all directions if possible.7 Margins must include bone when the tumor is located on the maxilla or mandible, necessitating a partial or full maxillectomy or mandibulectomy (FIGURE 3).

Removal of locoregional lymph nodes with suspected or confirmed metastatic disease may be beneficial.17 Removal of normal locoregional lymph nodes is not routinely performed.18 Sentinel lymph node mapping is being investigated in veterinary medicine and may prove to be useful in identifying target nodes for lymphadenectomy.19,20

**TABLE 1 The World Health Organization Staging Scheme for Canine Oral Malignant Melanoma**

<table>
<thead>
<tr>
<th>Primary tumor size</th>
<th>STAGE I</th>
<th>STAGE II</th>
<th>STAGE III</th>
<th>STAGE IV</th>
</tr>
</thead>
<tbody>
<tr>
<td>T1 (≤2 cm in diameter)</td>
<td>T2 (2–4 cm in diameter)</td>
<td>T2 or T3 (&gt;4 cm in diameter)</td>
<td>Any T</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Regional lymph nodes</th>
<th>NO (no regional lymph node involvement)</th>
<th>NO</th>
<th>N1 (presence of regional lymph node metastasis) or N0</th>
<th>Any N, including N2 (fixed nodes)</th>
</tr>
</thead>
</table>

| Distant metastasis | MO (no evidence of distant metastasis) | MO | MO | M1 (presence of distant metastasis) |

62 • JANUARY/FEBRUARY 2021 • todaysveterinarypractice.com
Dogs that undergo oral surgery, including maxillectomy and mandibulectomy, have good cosmetic and functional outcomes (FIGURE 3). They enjoy a great quality of life, and many dogs adapt to their new jaw conformation and learn how to eat as early as 3 days after surgery.16 Ptyalism that reduces over time is the most commonly noted long-term side effect, especially after mandibulectomy.7

Radiation
Radiation therapy is another option for treatment of locoregional disease. Melanomas are considered to be relatively radioresistant tumors that may respond better to higher doses of radiation per fraction.21 A variety of radiation protocols have been described in veterinary literature.16 They typically consist of 3 to 6 treatments delivered either daily or weekly.22-24 Total doses of more than 30 Gy are associated with better tumor response.22-24 In the authors’ institution, a protocol of 4 weekly fractions of 8 Gy is preferred for both microscopic and gross OMM.

FIGURE 2. (A) Transverse and (B) sagittal computed tomographic image of oral malignant melanoma in the same dog as Figure 1. There is a lobular, soft tissue-attenuating, mildly heterogeneously contrast-enhancing mass with ill-defined margins associated with the buccal aspect of the gingiva of the left rostral maxilla (circled). This mass extends from the caudal aspect of the canine tooth to the rostral aspect of the fourth premolar and measures approximately 2.3 (W) x 1.8 (H) x 3.3 (L) cm. The central portion of this mass is non-contrast enhancing, with peripheral rim enhancement.

FIGURE 3. (A) Preoperative, (B) intraoperative, and (C) postoperative images of a dog with oral malignant melanoma of the left labial mucosa located dorsal to the first molar. The tumor was excised with 2-cm margins via a rim maxillectomy.
Chemotherapy and Immunotherapy

Chemotherapy has a limited role in management of canine OMM. The overall response rates in dogs with gross disease have been low, with the most promising rates being 18% for cisplatin and piroxicam\textsuperscript{25} and 28% for carboplatin.\textsuperscript{26} Moreover, multiple studies have failed to identify a survival benefit with addition of chemotherapy to surgery and radiation.\textsuperscript{24-26}

Systemic immunotherapy for adjuvant treatment of canine melanoma may be more promising than chemotherapy. A xenogeneic DNA vaccine, Oncept (Boehringer Ingelheim, petcancervaccine.com), has made headway as the first conditionally approved immunotherapy for the treatment of canine OMM. Initial literature described promising activity against OMM: dogs with stage II and III OMM treated with Oncept after surgical resection (with or without radiation therapy) had longer median survival times (MSTs) than dogs in the control group.\textsuperscript{27} Subsequent studies failed to show similar significant differences in survival.\textsuperscript{28-30} However, these studies were retrospective, with small numbers of patients in vaccinated and nonvaccinated groups, among other weaknesses inherent to retrospective studies, and should be interpreted with caution. Other retrospective studies have shown evidence of complete responses to Oncept alone in dogs with gross disease.\textsuperscript{28,29}

Based on the current body of research, Oncept melanoma vaccine is safe and easy to administer and may be an effective adjuvant systemic therapy for dogs with OMM.\textsuperscript{27,30} The authors believe that Oncept’s pitfalls and potential benefits should be discussed with owners on a case-by-case basis.

PROGNOSIS

The overall prognosis for OMM remains guarded. Most dogs die of metastatic disease. Dogs that undergo radical surgery that includes 2- to 3-cm bone and 1-cm soft tissue margins, or surgery and radiation therapy, have longer MSTs than dogs that receive no treatment.\textsuperscript{23,31} Overall, MSTs after complete excision are 1 to 2 years for stage I disease, 6 months to 2 years for stage II, and 5 to 8 months for stage III.\textsuperscript{31}

<table>
<thead>
<tr>
<th>TABLE 2 Prognostic Indicators for Canine Oral Malignant Melanoma</th>
</tr>
</thead>
<tbody>
<tr>
<td>PROGNOSTIC FACTORS</td>
</tr>
<tr>
<td>Age\textsuperscript{22,32}</td>
</tr>
<tr>
<td>Stage\textsuperscript{16,23}</td>
</tr>
<tr>
<td>Tumor size\textsuperscript{22,31}</td>
</tr>
<tr>
<td>Bone lysis\textsuperscript{22-28}</td>
</tr>
<tr>
<td>Histology\textsuperscript{28}</td>
</tr>
<tr>
<td>Immunohistochemistry\textsuperscript{22}</td>
</tr>
<tr>
<td>Location\textsuperscript{7,22}</td>
</tr>
</tbody>
</table>

WHO=World Health Organization
Dogs with nonresectable tumors have shorter progression-free survival and MSTs. In a report looking at radiation as a sole treatment for dogs with macroscopic OMM, MSTs were highly variable.\(^1\) Dogs showing no negative prognostic indicators had an MST of up to 21 months; MST for dogs with 1, 2, or 3 negative prognostic indicators was 11, 5, and 3 months, respectively. **TABLE 2** lists prognostic factors for canine OMM. **TVP**

**References**


6. Wingo K. Histopathologic diagnoses from biopsies of the oral cavity in 3 months, respectively.


**Brian T. Meyer**

Dr. Meyer is a medical oncology intern at the University of Tennessee College of Veterinary Medicine. He received his veterinary degree at Kansas State University and completed an internship at the University of Missouri. His special interests include canine osteosarcoma and immunotherapy.

**Olya Martin**

Dr. Martin is a clinical associate professor in oncology at the University of Tennessee College of Veterinary Medicine. She received her DVM at the University of Tennessee and completed a rotating internship at the University of Illinois and a residency in oncology at the University of Tennessee. Dr. Martin’s special interests include canine and feline lymphoma, tyrosine kinase inhibitors, and metronomic chemotherapy.